{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:08:45Z","timestamp":1792807725132,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"1_suppl","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>About 20%\u201325% of all intracerebral haemorrhages are associated with oral anticoagulation therapy. Reflecting changings prescription patterns in the general population, the spectrum of oral anticoagulation-associated intracerebral haemorrhage has substantially changed in the last decade. In many European countries, direct oral anticoagulant-associated intracerebral haemorrhage is now more frequent than vitamin K antagonist-associated intracerebral haemorrhage. Outcome in patients with anticoagulation-associated intracerebral haemorrhage is poor, likely mediated by a high incidence of haematoma expansion. Reversal of anticoagulation is an essential part of current care pathways for hyperacute treatment of intracerebral haemorrhage aiming to limit haematoma expansion and thereby improving outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this review, we summarise the latest evidence regarding reversal therapy for vitamin K antagonist-, direct thrombin inhibitor- and factor Xa inhibitor-associated intracerebral haemorrhage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>Two randomised controlled trials have shown that the use of prothrombin complex concentrate (compared to fresh frozen plasma) for reversing vitamin K antagonist-associated intracerebral haemorrhage and andexanet alfa (compared to usual care, mainly prothrombin complex concentrate) for factor Xa inhibitor-associated intracerebral haemorrhage had superior haemostatic efficacy. However, the incidence of thromboembolic complications was high in both trials. For reversal of Vitamin K antagonist-associated intracerebral haemorrhage, the overall rate was 18% but due to crossovers, it is impossible to determine the rate for any specific treatment. For factor-Xa inhibitor associated intracerebral haemorrhage, andexanet alfa led to an increase in the incidence of thromboembolic events. Moreover, these two randomised controlled trials were not powered to detect differences in mortality or functional outcomes and lacked long-term follow-up. Idarucizumab has shown promising results in a single-arm case series of patients with intracerebral haemorrhage associated with the direct thrombin inhibitor dabigatran, yet no randomised controlled trial is available to support these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Given that haematoma expansion is strongly associated with poor outcome, current evidence underlines the importance of rapid, targeted and effective reversal of anticoagulation in patients with anticoagulation-associated intracerebral haemorrhage. While haematoma expansion is a key prognostic factor, no randomised controlled trial has demonstrated a clear improvement in functional outcome. Future research should weigh the advantages of preventing haematoma expansion against the risks of increased thromboembolic events, and aim to identify the patients who would derive the most benefit from reversal treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873241281477","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:00:24Z","timestamp":1747897224000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Reversal of anticoagulation in patients with intracerebral haemorrhage related to oral anticoagulants: State of the evidence"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-3849","authenticated-orcid":false,"given":"David","family":"Seiffge","sequence":"first","affiliation":[{"name":"Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-2208","authenticated-orcid":false,"given":"Alexandros","family":"Polymeris","sequence":"additional","affiliation":[{"name":"Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waltraud","family":"Pfeilschifter","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany 3"},{"name":"Department of Neurology and Clinical Neurophysiology, St\u00e4dtisches Klinikum L\u00fcneburg, L\u00fcneburg, Germany 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-5476","authenticated-orcid":false,"given":"Trine","family":"Apostolaki-Hansson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-4992","authenticated-orcid":false,"given":"Bonaventure","family":"Ip","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Faculty of Medicine, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR 6"},{"name":"Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8999-5424","authenticated-orcid":false,"given":"Espen Saxhaug","family":"Kristoffersen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Medicine, Akershus University Hospital, L\u00f8renskog, Norway 8"},{"name":"Department of General Practice, University of Oslo, Oslo, Norway 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji B","family":"Kuramatsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Erlangen, Germany 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-4191","authenticated-orcid":false,"given":"Bernhard M","family":"Siepen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Inselspital University Hospital and University of Bern, Bern, Switzerland 1"},{"name":"Graduate School for Health Sciences, University of Bern, Bern, Switzerland 11"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2026012113081058500_bibr1-23969873241281477","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","author":"GBD 2019 Stroke Collaborators","year":"2021","journal-title":"Lancet Neurol"},{"key":"2026012113081058500_bibr2-23969873241281477","article-title":"Burden of intracerebral haemorrhage in Europe: forecasting incidence and mortality between 2019 and 2050","volume":"38","author":"Wafa","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026012113081058500_bibr3-23969873241281477","doi-asserted-by":"publisher","DOI":"10.1136\/svn-2023-002813","article-title":"Intracerebral haemorrhage in patients taking different types of oral anticoagulants: a pooled individual patient data analysis from two national stroke registries","author":"Siepen","journal-title":"Stroke Vasc Neurol"},{"key":"2026012113081058500_bibr4-23969873241281477","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non\u2013vitamin K antagonist vs vitamin K antagonist oral anticoagulants with In-hospital mortality","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"2026012113081058500_bibr5-23969873241281477","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/STROKEAHA.120.030930","article-title":"Prognosis of intracerebral hemorrhage related to antithrombotic use: an observational study from the Swedish Stroke Register (Riksstroke)","volume":"52","author":"Apostolaki-Hansson","year":"2021","journal-title":"Stroke"},{"key":"2026012113081058500_bibr6-23969873241281477","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026012113081058500_bibr7-23969873241281477","first-page":"805","article-title":"Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants","volume":"92","author":"Seiffge","year":"2021","journal-title":"J Neurol"},{"key":"2026012113081058500_bibr8-23969873241281477","doi-asserted-by":"crossref","first-page":"e023345","DOI":"10.1161\/JAHA.121.023345","article-title":"Differences between anticoagulated patients with ischemic stroke versus intracerebral hemorrhage","volume":"11","author":"Schaub","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026012113081058500_bibr9-23969873241281477","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9973","article-title":"Time Trends in patient characteristics, anticoagulation treatment, and prognosis of incident nonvalvular atrial fibrillation in the Netherlands","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026012113081058500_bibr10-23969873241281477","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436\u2009864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026012113081058500_bibr11-23969873241281477","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ane.13068","article-title":"Prognosis for intracerebral hemorrhage during ongoing oral anticoagulant treatment","volume":"139","author":"Apostolaki-Hansson","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"2026012113081058500_bibr12-23969873241281477","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1007\/s00415-019-09536-1","article-title":"Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use","volume":"266","author":"Seiffge","year":"2019","journal-title":"J Neurol"},{"key":"2026012113081058500_bibr13-23969873241281477","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/STROKEAHA.116.013343","article-title":"Anticoagulant-associated intracranial hemorrhage in the era of reversal agents","volume":"48","author":"Steiner","year":"2017","journal-title":"Stroke"},{"key":"2026012113081058500_bibr14-23969873241281477","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/STROKEAHA.122.041246","article-title":"Location-specific hematoma volume cutoff and clinical outcomes in intracerebral hemorrhage","volume":"54","author":"Teo","year":"2023","journal-title":"Stroke"},{"key":"2026012113081058500_bibr15-23969873241281477","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.15859","article-title":"Disability-adjusted life-years associated with intracerebral hemorrhage and Secondary Injury","volume":"4","author":"Haupenthal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026012113081058500_bibr16-23969873241281477","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1212\/WNL.0000000000006958","article-title":"Hematoma location and morphology of anticoagulation-associated intracerebral hemorrhage","volume":"92","author":"Seiffge","year":"2019","journal-title":"Neurology"},{"key":"2026012113081058500_bibr17-23969873241281477","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(18)30253-9","article-title":"Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data","volume":"17","author":"Al-Shahi Salman","year":"2018","journal-title":"Lancet Neurol"},{"key":"2026012113081058500_bibr18-23969873241281477","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaneurol.2024.0221","article-title":"Time to anticoagulation reversal and outcomes after intracerebral hemorrhage","volume":"81","author":"Sheth","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026012113081058500_bibr19-23969873241281477","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(23)00806-1","article-title":"The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial","volume":"402","author":"Ma","year":"2023","journal-title":"Lancet"},{"key":"2026012113081058500_bibr20-23969873241281477","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.25546","article-title":"An intracerebral hemorrhage care bundle is associated with lower case fatality","volume":"86","author":"Parry-Jones","year":"2019","journal-title":"Ann Neurol"},{"key":"2026012113081058500_bibr21-23969873241281477","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/23969873231220235","article-title":"Acute care bundles should be used for patients with intracerebral haemorrhage: an expert consensus statement","volume":"9","author":"Parry-Jones","year":"2024","journal-title":"Eur Stroke J"},{"key":"2026012113081058500_bibr22-23969873241281477","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.21469","article-title":"Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment","volume":"84","author":"Ageno","year":"2009","journal-title":"Am J Hematol"},{"key":"2026012113081058500_bibr23-23969873241281477","first-page":"148","article-title":"Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage","volume":"9","author":"Imberti","year":"2011","journal-title":"Blood Transfus"},{"key":"2026012113081058500_bibr24-23969873241281477","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM197010082831508","article-title":"Warfarin therapy. 2","volume":"283","author":"Deykin","year":"1970","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr25-23969873241281477","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM197009242831307","article-title":"Warfarin therapy. 1","volume":"283","author":"Deykin","year":"1970","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr26-23969873241281477","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"2026012113081058500_bibr27-23969873241281477","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","article-title":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial","volume":"385","author":"Goldstein","year":"2015","journal-title":"Lancet"},{"key":"2026012113081058500_bibr28-23969873241281477","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"2026012113081058500_bibr29-23969873241281477","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ana.24416","article-title":"Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage","volume":"78","author":"Parry-Jones","year":"2015","journal-title":"Ann Neurol"},{"key":"2026012113081058500_bibr30-23969873241281477","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"2026012113081058500_bibr31-23969873241281477","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12873-022-00568-x","article-title":"Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis","volume":"22","author":"Margraf","year":"2022","journal-title":"BMC Emerg Med"},{"key":"2026012113081058500_bibr32-23969873241281477","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr33-23969873241281477","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr34-23969873241281477","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1177\/1747493019895654","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-updated series of 120 cases","volume":"15","author":"Kermer","year":"2020","journal-title":"Int J Stroke"},{"key":"2026012113081058500_bibr35-23969873241281477","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr36-23969873241281477","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr37-23969873241281477","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr38-23969873241281477","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/ijs.12309","article-title":"European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage","volume":"9","author":"Steiner","year":"2014","journal-title":"Int J Stroke"},{"key":"2026012113081058500_bibr39-23969873241281477","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"key":"2026012113081058500_bibr40-23969873241281477","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"2026012113081058500_bibr41-23969873241281477","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur Stroke J"},{"key":"2026012113081058500_bibr42-23969873241281477","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexan alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr43-23969873241281477","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","article-title":"Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann Neurol"},{"key":"2026012113081058500_bibr44-23969873241281477","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54916","article-title":"Prothrombin complex concentrate vs conservative management in ICH associated with direct oral anticoagulants","volume":"7","author":"Ip","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026012113081058500_bibr45-23969873241281477","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1161\/STROKEAHA.123.042866","article-title":"Tranexamic acid for intracerebral hemorrhage in patients on non-vitamin K antagonist oral anticoagulants (TICH-NOAC): A multicenter, randomized, Placebo-Controlled, Phase 2 Trial","volume":"54","author":"Polymeris","year":"2023","journal-title":"Stroke"},{"key":"2026012113081058500_bibr46-23969873241281477","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/STROKEAHA.120.030565","article-title":"Hemostatic efficacy and anti-FXa (Factor Xa) reversal with andexan alfa in intracranial hemorrhage: ANNEXA-4 substudy","volume":"52","author":"Demchuk","year":"2021","journal-title":"Stroke"},{"key":"2026012113081058500_bibr47-23969873241281477","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/17474930241230209","article-title":"Andexan alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors \u2014 individual patient data analysis of ANNEXA-4 and TICH-NOAC","volume":"19","author":"Siepen","year":"2024","journal-title":"Int J Stroke"},{"key":"2026012113081058500_bibr48-23969873241281477","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1056\/NEJMc2407378","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"391","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012113081058500_bibr49-23969873241281477","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1212\/WNL.0b013e3182143317","article-title":"Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes","volume":"76","author":"Dowlatshahi","year":"2011","journal-title":"Neurology"},{"key":"2026012113081058500_bibr50-23969873241281477","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/STROKEAHA.121.034572","article-title":"Hematoma expansion and clinical outcomes in patients with factor-Xa inhibitor-related atraumatic intracerebral hemorrhage treated within the ANNEXA-4 trial versus real-world usual care","volume":"53","author":"Huttner","year":"2022","journal-title":"Stroke"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873241281477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873241281477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/14\/64645693\/23969873241281477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/14\/64645693\/23969873241281477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:08:49Z","timestamp":1769018929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/1_suppl\/14\/8268623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":50,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873241281477","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,1]]},"published":{"date-parts":[[2025,4,1]]}}}